Clinical Trials
18 trialsNCT03431350 2026-05-11
QUEST
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT05335993 2026-04-03
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
CanariaBio Inc.
Phase 2 Active not recruiting
NCT06433219 2026-02-18
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
EMD Serono
Phase 2 Active not recruiting
NCT02854436 2025-12-22
Galahad
Janssen Research & Development, LLC
Phase 2 Completed
NCT06964165 2025-11-26
A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)
Tesaro, Inc.
Phase 2 Terminated
NCT05169437 2025-10-29
PAVO
Tempus AI
Phase 2 Terminated
NCT04641247 2025-09-29
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
GlaxoSmithKline
Phase 2 Recruiting
NCT03326193 2025-07-31
A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Tesaro, Inc.
Phase 2 Completed
NCT03574779 2025-07-15
OPAL
Tesaro, Inc.
Phase 2 Completed
NCT05126342 2025-04-06
Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
AGO Research GmbH
Phase 2 Withdrawn
NCT03759600 2024-07-16
Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer
Takeda
Phase 2 Completed
NCT03759587 2024-06-07
Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer
Takeda
Phase 2 Completed
NCT03308942 2023-10-16
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
Tesaro, Inc.
Phase 2 Completed
NCT05751629 2023-04-21
COHORT-A
Tesaro, Inc.
Phase 2 Completed
NCT02354586 2022-09-15
QUADRA
Tesaro, Inc.
Phase 2 Completed
NCT03955471 2022-09-10
MOONSTONE
Tesaro, Inc.
Phase 2 Terminated
NCT04392102 2022-08-29
A Study of Niraparib in Patients With Relapsed Ovarian Cancer
Zai Lab (Hong Kong), Ltd.
Phase 2 Completed
NCT01244009 2016-11-07
A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)
Tesaro, Inc.
Phase 2 Withdrawn